• Explore /
  • Poster
  • / First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

Abstract Poster

Authors

null

Elena Ioana Braicu

Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum and North-Eastern German Society of Gynaecological Oncology (NOGGO) and Stanford University, Berlin, Germany

Elena Ioana Braicu , Klaus Pietzner , Dario Zocholl , Purificación Estévez-García , Dionyssios Katsaros , Toon Van Gorp , Regina Berger , Maren Keller , Jalid Sehouli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT05460000

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5620)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5620

Abstract #

TPS5620

Poster Bd #

311a

Abstract Disclosures

Similar Posters

First Author: Elena Ioana Braicu

First Author: Florian Heitz

First Author: Patricia Pautier

First Author: Joanie M. Hope